Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cardiovascular Translational Research
Published in: Journal of Cardiovascular Translational Research 2/2014

01-03-2014

Targeting Matrix Metalloproteinase Activity and Expression for the Treatment of Viral Myocarditis

Authors: Reid G. Hendry, Leanne M. Bilawchuk, David J. Marchant

Published in: Journal of Cardiovascular Translational Research | Issue 2/2014

Login to get access

Abstract

Infectious agents including viruses can infect the heart muscle, resulting in the development of heart inflammation called myocarditis. Chronic myocarditis can lead to dilated cardiomyopathy (DCM). DCM develops from the extensive extracellular matrix (ECM) remodeling caused by myocarditis and may result in heart failure. Epidemiological data for viral myocarditis has long suggested a worse pathology in males, with more recent data demonstrating sex-dependent pathogenesis in DCM as well. Matrix metalloproteinases (MMPs), long known modulators of the extracellular matrix, have important roles in mediating heart inflammation and remodeling during disease and in convalescence. This ability of MMPs to control both the inflammatory response and ECM remodeling during myocarditis makes them potential drug targets. In this review, we analyze the role of MMPs in mediating myocarditis/DCM disease progression, their sex-dependent expression, and their potential as drug targets during viral myocarditis and DCM.
Literature
1.
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., et al. (2013). Heart disease and stroke statistics—2013 update a report from the American Heart Association. Circulation, 127(1), E6–E245. doi:10.​1161/​Cir.​0b013e31828124ad​.PubMed
2.
3.
4.
Coronado, M. J., Brandt, J. E., Kim, E., Bucek, A., Bedja, D., Abston, E. D., et al. (2012). Testosterone and interleukin-1beta increase cardiac remodeling during coxsackievirus B3 myocarditis via serpin A 3n. American Journal of Physiology Heart and Circulatory Physiology, 302(8), H1726–H1736. doi:10.​1152/​ajpheart.​00783.​2011.PubMed
5.
Bishop, J. E., Greenbaum, R., Gibson, D. G., Yacoub, M., & Laurent, G. J. (1990). Enhanced deposition of predominantly type I collagen in myocardial disease. Journal of Molecular and Cellular Cardiology, 22(10), 1157–1165.PubMed
6.
Klappacher, G., Franzen, P., Haab, D., Mehrabi, M., Binder, M., Plesch, K., et al. (1995). Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. The American Journal of Cardiology, 75(14), 913–918.PubMed
7.
Yoshikane, H., Honda, M., Goto, Y., Morioka, S., Ooshima, A., & Moriyama, K. (1992). Collagen in dilated cardiomyopathy—scanning electron microscopic and immunohistochemical observations. Japanese Circulation Journal, 56(9), 899–910.PubMed
8.
Marijianowski, M. M., Teeling, P., Mann, J., & Becker, A. E. (1995). Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. Journal of the American College of Cardiology, 25(6), 1263–1272. doi:10.​1016/​0735-1097(94)00557-7.PubMed
9.
Gross, J., & Lapiere, C. M. (1962). Collagenolytic activity in amphibian tissues: a tissue culture assay. Proceedings of the National Academy of Sciences of the United States of America, 48, 1014–1022.PubMedCentralPubMed
10.
11.
Chakraborti, S., Mandal, M., Das, S., Mandal, A., & Chakraborti, T. (2003). Regulation of matrix metalloproteinases: an overview. Molecular and Cellular Biochemistry, 253(1–2), 269–285.PubMed
12.
Marchenko, G. N., Ratnikov, B. I., Rozanov, D. V., Godzik, A., Deryugina, E. I., & Strongin, A. Y. (2001). Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. The Biochemical Journal, 356(Pt 3), 705–718.PubMed
13.
Shapiro, S. D., Kobayashi, D. K., & Ley, T. J. (1993). Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. The Journal of Biological Chemistry, 268(32), 23824–23829.PubMed
14.
Li, J., Schwimmbeck, P. L., Tschope, C., Leschka, S., Husmann, L., Rutschow, S., et al. (2002). Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovascular Research, 56(2), 235–247.PubMed
15.
McQuibban, G. A., Gong, J. H., Wong, J. P., Wallace, J. L., Clark-Lewis, I., & Overall, C. M. (2002). Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood, 100(4), 1160–1167.PubMed
16.
McQuibban, G. A., Gong, J. H., Tam, E. M., McCulloch, C. A., Clark-Lewis, I., & Overall, C. M. (2000). Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science, 289(5482), 1202–1206.PubMed
17.
Dean, R. A., Cox, J. H., Bellac, C. L., Doucet, A., Starr, A. E., & Overall, C. M. (2008). Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR + CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood, 112(8), 3455–3464. doi:10.​1182/​blood-2007-12-129080.PubMed
18.
Overall, C. M., McQuibban, G. A., & Clark-Lewis, I. (2002). Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biological Chemistry, 383(7–8), 1059–1066. doi:10.​1515/​BC.​2002.​114.PubMed
19.
Opdenakker, G., Van den Steen, P. E., Dubois, B., Nelissen, I., Van Coillie, E., Masure, S., et al. (2001). Gelatinase B functions as regulator and effector in leukocyte biology. Journal of Leukocyte Biology, 69(6), 851–859.PubMed
20.
Starr, A. E., Dufour, A., Maier, J., & Overall, C. M. (2012). Biochemical analysis of matrix metalloproteinase activation of chemokines CCL15 and CCL23 and increased glycosaminoglycan binding of CCL16. The Journal of Biological Chemistry, 287(8), 5848–5860. doi:10.​1074/​jbc.​M111.​314609.PubMed
21.
22.
Balbin, M., Fueyo, A., Tester, A. M., Pendas, A. M., Pitiot, A. S., Astudillo, A., et al. (2003). Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nature Genetics, 35(3), 252–257. doi:10.​1038/​ng1249.PubMed
23.
Churg, A., Wang, R. D., Tai, H., Wang, X., Xie, C., Dai, J., et al. (2003). Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. American Journal of Respiratory and Critical Care Medicine, 167(8), 1083–1089. doi:10.​1164/​rccm.​200212-1396OC.PubMed
24.
Cox, J. H., Starr, A. E., Kappelhoff, R., Yan, R., Roberts, C. R., & Overall, C. M. (2010). Matrix metalloproteinase 8 deficiency in mice exacerbates inflammatory arthritis through delayed neutrophil apoptosis and reduced caspase 11 expression. Arthritis and Rheumatism, 62(12), 3645–3655. doi:10.​1002/​art.​27757.PubMed
25.
Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S. A., et al. (1999). MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell, 99(1), 81–92.PubMed
26.
Yong, V. W., Krekoski, C. A., Forsyth, P. A., Bell, R., & Edwards, D. R. (1998). Matrix metalloproteinases and diseases of the CNS. Trends in Neurosciences, 21(2), 75–80.PubMed
27.
Brew, K., Dinakarpandian, D., & Nagase, H. (2000). Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et Biophysica Acta, 1477(1–2), 267–283.PubMed
28.
Will, H., Atkinson, S. J., Butler, G. S., Smith, B., & Murphy, G. (1996). The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. The Journal of Biological Chemistry, 271(29), 17119–17123.PubMed
29.
Crocker, S. J., Pagenstecher, A., & Campbell, I. L. (2004). The TIMPs tango with MMPs and more in the central nervous system. Journal of Neuroscience Research, 75(1), 1–11. doi:10.​1002/​jnr.​10836.PubMed
30.
Caterina, J. J., Yamada, S., Caterina, N. C., Longenecker, G., Holmback, K., Shi, J., et al. (2000). Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2(Timp-2) gene alters proMMP-2 activation. The Journal of Biological Chemistry, 275(34), 26416–26422. doi:10.​1074/​jbc.​M001271200.PubMed
31.
32.
33.
Lee, R. T., Schoen, F. J., Loree, H. M., Lark, M. W., & Libby, P. (1996). Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arteriosclerosis Thrombosis and Vascular Biology, 16(8), 1070–1073.
34.
Nikkari, S. T., O'Brien, K. D., Ferguson, M., Hatsukami, T., Welgus, H. G., Alpers, C. E., et al. (1995). Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation, 92(6), 1393–1398.PubMed
35.
36.
37.
Cheung, C., Luo, H., Yanagawa, B., Leong, H. S., Samarasekera, D., Lai, J. C., et al. (2006). Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cardiovascular Pathology : The Official Journal of the Society for Cardiovascular Pathology, 15(2), 63–74. doi:10.​1016/​j.​carpath.​2005.​11.​008.
38.
Raza, S. L., Nehring, L. C., Shapiro, S. D., & Cornelius, L. A. (2000). Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases. The Journal of Biological Chemistry, 275(52), 41243–41250. doi:10.​1074/​jbc.​M005788200.PubMed
39.
Weiss, S. J., Peppin, G., Ortiz, X., Ragsdale, C., & Test, S. T. (1985). Oxidative autoactivation of latent collagenase by human neutrophils. Science, 227(4688), 747–749.PubMed
40.
Cowland, J. B., & Borregaard, N. (1999). The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. Journal of Leukocyte Biology, 66(6), 989–995.PubMed
41.
Rutschow, S., Leschka, S., Westermann, D., Puhl, K., Weitz, A., Ladyszenskij, L., et al. (2010). Left ventricular enlargement in coxsackievirus-B3 induced chronic myocarditis—ongoing inflammation and an imbalance of the matrix degrading system. European Journal of Pharmacology, 630(1–3), 145–151. doi:10.​1016/​j.​ejphar.​2009.​12.​019.PubMed
42.
43.
44.
Agrawal, S., Anderson, P., Durbeej, M., van Rooijen, N., Ivars, F., Opdenakker, G., et al. (2006). Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. The Journal of Experimental Medicine, 203(4), 1007–1019. doi:10.​1084/​jem.​20051342.PubMedCentralPubMed
45.
46.
Romanic, A. M., & Madri, J. A. (1994). The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. The Journal of Cell Biology, 125(5), 1165–1178.PubMed
47.
Cheung, C. T., Deisher, T. A., Luo, H., Yanagawa, B., Bonigut, S., Samra, A., et al. (2007). Neutralizing anti-4-1BBL treatment improves cardiac function in viral myocarditis. Laboratory investigation: a Journal of Technical Methods and Pathology, 87(7), 651–661. doi:10.​1038/​labinvest.​3700563.
48.
Westermann, D., Savvatis, K., Lindner, D., Zietsch, C., Becher, P. M., Hammer, E., et al. (2011). Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation, 124(19), 2082–2093. doi:10.​1161/​CIRCULATIONAHA.​111.​035964.PubMed
49.
50.
Nelissen, I., Martens, E., Van den Steen, P. E., Proost, P., Ronsse, I., & Opdenakker, G. (2003). Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain : a Journal of Neurology, 126(Pt 6), 1371–1381.
51.
Heymans, S., Pauschinger, M., De Palma, A., Kallwellis-Opara, A., Rutschow, S., Swinnen, M., et al. (2006). Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation, 114(6), 565–573. doi:10.​1161/​CIRCULATIONAHA.​105.​591032.PubMed
52.
Overall, C. M., & Kleifeld, O. (2006). Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Reviews Cancer, 6(3), 227–239. doi:10.​1038/​nrc1821.PubMed
53.
Anonymous (1996) Agouron and Roche initiate clinical trials of anticancer MMP inhibitor AG-3340. Drug News Perspect 9 (8):484-484
54.
Naito, S., Takahashi, T., Onoda, J., Yamauchi, A., Kawai, T., Kishino, J., et al. (2012). Development of a neutralizing antibody specific for the active form of matrix metalloproteinase-13. Biochemistry, 51(44), 8877–8884. doi:10.​1021/​bi301228d.PubMed
55.
Devel, L., Rogakos, V., David, A., Makaritis, A., Beau, F., Cuniasse, P., et al. (2006). Development of selective inhibitors and substrate of matrix metalloproteinase-12. The Journal of Biological Chemistry, 281(16), 11152–11160. doi:10.​1074/​jbc.​M600222200.PubMed
56.
Fray, M. J., & Dickinson, R. P. (2001). Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). Bioorganic & Medicinal Chemistry Letters, 11(4), 571–574.
57.
Grobelny, D., Poncz, L., & Galardy, R. E. (1992). Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry, 31(31), 7152–7154. doi:10.​1021/​Bi00146a017.PubMed
58.
59.
Rudek, M. A., Dyer, V., Hamilton, J. M., Pluda, J. M., Reed, E., & Figg, W. D. (1999). Preliminary pharmacokinetics (PK) of COL-3, a matrix metalloproteinase (MMP) inhibitor. Clinical Pharmacology and Therapeutics, 65(2), 195. doi:10.​1016/​S0009-9236(99)80308-7.
60.
61.
Devy, L., Huang, L., Naa, L., Yanamandra, N., Pieters, H., Frans, N., et al. (2009). Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Research, 69(4), 1517–1526. doi:10.​1158/​0008-5472.​CAN-08-3255.PubMed
62.
Li, W., Li, J., Wu, Y., Wu, J., Hotchandani, R., Cunningham, K., et al. (2009). A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b, d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408). Journal of Medicinal Chemistry, 52(7), 1799–1802. doi:10.​1021/​jm900093d.PubMed
63.
Davies, B., Brown, P. D., East, N., Crimmin, M. J., & Balkwill, F. R. (1993). A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Research, 53(9), 2087–2091.PubMed
64.
Bissett, D., O'Byrne, K. J., von Pawel, J., Gatzemeier, U., Price, A., Nicolson, M., et al. (2005). Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 23(4), 842–849. doi:10.​1200/​JCO.​2005.​03.​170.
65.
Bramhall, S. R., Hallissey, M. T., Whiting, J., Scholefield, J., Tierney, G., Stuart, R. C., et al. (2002). Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. British Journal of Cancer, 86(12), 1864–1870. doi:10.​1038/​sj.​bjc.​6600310.PubMedCentralPubMed
66.
Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M., & Cravatt, B. F. (2004). Activity-based probes for the proteomic profiling of metalloproteases. Proceedings of the National Academy of Sciences of the United States of America, 101(27), 10000–10005. doi:10.​1073/​pnas.​0402784101.PubMedCentralPubMed
67.
Nakai, R., Salisbury, C. M., Rosen, H., & Cravatt, B. F. (2009). Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorganic & Medicinal Chemistry, 17(3), 1101–1108. doi:10.​1016/​j.​bmc.​2008.​03.​018.
68.
King, J., Zhao, J., Clingan, P., & Morris, D. (2003). Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Research, 23(1B), 639–645.PubMed
69.
70.
71.
Crocker, S. J., Frausto, R. F., Whitmire, J. K., Benning, N., Milner, R., & Whitton, J. L. (2007). Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1. The American Journal of Pathology, 171(6), 1762–1773. doi:10.​2353/​ajpath.​2007.​070179.PubMed
72.
Dorman, G., Cseh, S., Hajdu, I., Barna, L., Konya, D., Kupai, K., et al. (2010). Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs, 70(8), 949–964. doi:10.​2165/​11318390-000000000-00000.PubMed
73.
Czarny, B., Stura, E. A., Devel, L., Vera, L., Cassar-Lajeunesse, E., Beau, F., et al. (2013). Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies. Journal of Medicinal Chemistry, 56(3), 1149–1159. doi:10.​1021/​jm301574d.PubMed
74.
Ingvarsen, S., Porse, A., Erpicum, C., Maertens, L., Jurgensen, H. J., Madsen, D. H., et al. (2013). Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis. The Journal of Biological Chemistry, 288(15), 10195–10204. doi:10.​1074/​jbc.​M112.​447169.PubMed
75.
Seizer, P., Klingel, K., Sauter, M., Westermann, D., Ochmann, C., Schonberger, T., et al. (2012). Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3-induced myocarditis. Journal of Molecular and Cellular Cardiology, 53(1), 6–14. doi:10.​1016/​j.​yjmcc.​2012.​03.​004.PubMed
76.
Arola, A., Tuominen, J., Ruuskanen, O., & Jokinen, E. (1998). Idiopathic dilated cardiomyopathy in children: prognostic indicators and outcome. Pediatrics, 101(3 Pt 1), 369–376.PubMed
77.
Cocker, M. S., Abdel-Aty, H., Strohm, O., & Friedrich, M. G. (2009). Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study. Heart, 95(23), 1925–1930. doi:10.​1136/​hrt.​2008.​164061.PubMed
78.
79.
Viegi, G., Scognamiglio, A., Baldacci, S., Pistelli, F., & Carrozzi, L. (2001). Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration, 68(1), 4–19. International Review of Thoracic Diseases.PubMed
80.
Narayan, K. M., Boyle, J. P., Thompson, T. J., Sorensen, S. W., & Williamson, D. F. (2003). Lifetime risk for diabetes mellitus in the United States. JAMA : the Journal of the American Medical Association, 290(14), 1884–1890. doi:10.​1001/​jama.​290.​14.​1884.
81.
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., et al. (2012). Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation, 125(1), e2–e220. doi:10.​1161/​CIR.​0b013e31823ac046​.PubMed
82.
83.
84.
85.
Kintzel, P. E., Chase, S. L., Schultz, L. M., & O'Rourke, T. J. (2008). Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy, 28(12), 1511–1522. doi:10.​1592/​phco.​28.​12.​1511.PubMed
86.
MacLean, H. E., Warne, G. L., & Zajac, J. D. (1995). Defects of androgen receptor function: from sex reversal to motor neurone disease. Molecular and Cellular Endocrinology, 112(2), 133–141.PubMed
87.
88.
Vassilatou, E., Lafoyianni, S., Vryonidou, A., Ioannidis, D., Kosma, L., Katsoulis, K., et al. (2010). Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Human Reproduction, 25(1), 212–220. doi:10.​1093/​humrep/​dep380.PubMed
89.
90.
Vashist, S., & Singh, G. K. (2009). Acute myocarditis in children: current concepts and management. Current Treatment Options in Cardiovascular Medicine, 11(5), 383–391.PubMed
91.
92.
93.
Kearney, M. T., Cotton, J. M., Richardson, P. J., & Shah, A. M. (2001). Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgraduate Medical Journal, 77(903), 4–10.PubMed
94.
Haddad, G. E., Saunders, L. J., Crosby, S. D., Carles, M., del Monte, F., King, K., et al. (2008). Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences. Physiological Genomics, 33(2), 267–277. doi:10.​1152/​physiolgenomics.​00265.​2007.PubMed
95.
Huber, S. A., Job, L. P., & Auld, K. R. (1982). Influence of sex hormones on Coxsackie B-3 virus infection in Balb/c mice. Cellular Immunology, 67(1), 173–179.PubMed
96.
Frisancho-Kiss, S., Coronado, M. J., Frisancho, J. A., Lau, V. M., Rose, N. R., Klein, S. L., et al. (2009). Gonadectomy of male BALB/c mice increases Tim-3(+) alternatively activated M2 macrophages, Tim-3(+) T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behavior and Immunity, 23(5), 649–657. doi:10.​1016/​j.​bbi.​2008.​12.​002.
97.
Huber, S. A., Kupperman, J., & Newell, M. K. (1999). Estradiol prevents and testosterone promotes Fas-dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression. Lupus, 8(5), 384–387.PubMed
98.
Huber, S. A., & Pfaeffle, B. (1994). Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. Journal of Virology, 68(8), 5126–5132.PubMedCentralPubMed
99.
Li, K., Xu, W., Guo, Q., Jiang, Z., Wang, P., Yue, Y., et al. (2009). Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circulation Research, 105(4), 353–364. doi:10.​1161/​CIRCRESAHA.​109.​195230.PubMed
100.
Pelzer, T., Schumann, M., Neumann, M., deJager, T., Stimpel, M., Serfling, E., et al. (2000). 17beta-estradiol prevents programmed cell death in cardiac myocytes. Biochemical and Biophysical Research Communications, 268(1), 192–200. doi:10.​1006/​bbrc.​2000.​2073.PubMed
101.
Samnegard, A., Hulthe, J., Silveira, A., Ericsson, C. G., Hamsten, A., & Eriksson, P. (2009). Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients. Atherosclerosis, 202(2), 550–556. doi:10.​1016/​j.​atherosclerosis.​2008.​05.​050.PubMed
102.
Komosinska-Vassev, K., Olczyk, P., Winsz-Szczotka, K., Kuznik-Trocha, K., Klimek, K., & Olczyk, K. (2011). Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level. Gerontology, 57(1), 44–52. doi:10.​1159/​000295775.PubMed
103.
Voloshenyuk, T. G., & Gardner, J. D. (2010). Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females. American Journal of Physiology Regulatory Integrative and Comparative Physiology, 299(2), R683–R693. doi:10.​1152/​ajpregu.​00162.​2010.
104.
Mahmoodzadeh, S., Dworatzek, E., Fritschka, S., Pham, T. H., & Regitz-Zagrosek, V. (2010). 17beta-Estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblasts. Cardiovascular Research, 85(4), 719–728. doi:10.​1093/​cvr/​cvp350.PubMed
105.
Woodrum, D. T., Ford, J. W., Ailawadi, G., Pearce, C. G., Sinha, I., Eagleton, M. J., et al. (2005). Gender differences in rat aortic smooth muscle cell matrix metalloproteinase-9. Journal of the American College of Surgeons, 201(3), 398–404. doi:10.​1016/​j.​jamcollsurg.​2005.​04.​002.PubMed
106.
Ehrlichman, L. K., Ford, J. W., Roelofs, K. J., Tedeschi-Filho, W., Futchko, J. S., Ramacciotti, E., et al. (2010). Gender-dependent differential phosphorylation in the ERK signaling pathway is associated with increased MMP2 activity in rat aortic smooth muscle cells. The Journal of Surgical Research, 160(1), 18–24. doi:10.​1016/​j.​jss.​2009.​03.​095.PubMedCentralPubMed
107.
108.
Ailawadi, G., Eliason, J. L., Roelofs, K. J., Sinha, I., Hannawa, K. K., Kaldjian, E. P., et al. (2004). Gender differences in experimental aortic aneurysm formation. Arteriosclerosis Thrombosis, and Vascular Biology, 24(11), 2116–2122. doi:10.​1161/​01.​ATV.​0000143386.​26399.​84.
109.
110.
111.
Arnlov, J., Pencina, M. J., Amin, S., Nam, B. H., Benjamin, E. J., Murabito, J. M., et al. (2006). Endogenous sex hormones and cardiovascular disease incidence in men. Annals of Internal Medicine, 145(3), 176–184.PubMed
112.
Fang, L., Gao, X. M., Moore, X. L., Kiriazis, H., Su, Y., Ming, Z., et al. (2007). Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. Journal of Molecular and Cellular Cardiology, 43(5), 535–544. doi:10.​1016/​j.​yjmcc.​2007.​06.​011.PubMed
113.
Tayebjee, M. H., Lip, G. Y., Tan, K. T., Patel, J. V., Hughes, E. A., & MacFadyen, R. J. (2005). Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. The American Journal of Cardiology, 96(3), 339–345. doi:10.​1016/​j.​amjcard.​2005.​03.​072.PubMed
114.
Shen, D., Tang, Q., Huang, Z., Chen, Y., Xiong, R., Wu, H., et al. (2009). The effects of NK4 on viral myocarditis mice. Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology, 18(6), 323–331. doi:10.​1016/​j.​carpath.​2008.​10.​008.
115.
Butler, G. S., & Overall, C. M. (2009). Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nature Reviews Drug Discovery, 8(12), 935–948. doi:10.​1038/​nrd2945.PubMed
116.
Cuadrado, E., Rosell, A., Borrell-Pages, M., Garcia-Bonilla, L., Hernandez-Guillamon, M., Ortega-Aznar, A., et al. (2009). Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia. Journal of Cerebral blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 29(2), 398–410. doi:10.​1038/​jcbfm.​2008.​130.
117.
118.
119.
Kwan, J. A., Schulze, C. J., Wang, W., Leon, H., Sariahmetoglu, M., Sung, M., et al. (2004). Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 18(6), 690–692. doi:10.​1096/​fj.​02-1202fje.
120.
121.
122.
Wiera, G., Wojtowicz, T., Lebida, K., Piotrowska, A., Drulis-Fajdasz, D., Gomulkiewicz, A., et al. (2012). Long term potentiation affects intracellular metalloproteinases activity in the mossy fiber-CA3 pathway. Molecular and Cellular Neurosciences, 50(2), 147–159. doi:10.​1016/​j.​mcn.​2012.​04.​005.PubMed
123.
Zimowska, M., Swierczynska, M., & Ciemerych, M. A. (2013). Nuclear MMP-9 role in the regulation of rat skeletal myoblasts proliferation. Biology of the Cell/Under the Auspices of the European Cell Biology Organization. doi:10.​1111/​boc.​201300020.PubMed
124.
Akaike, T., & Maeda, H. (2000). Nitric oxide and virus infection. Immunology, 101(3), 300–308.PubMed
125.
126.
127.
Iwasaki, A., Matsumori, A., Yamada, T., Shioi, T., Wang, W., Ono, K., et al. (1999). Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. Journal of the American College of Cardiology, 33(5), 1400–1407.PubMed
128.
Berger, N. A. (1985). Poly(ADP-ribose) in the cellular response to DNA damage. Radiation Research, 101(1), 4–15.PubMed
129.
Lowenstein, C. J., Hill, S. L., Lafond-Walker, A., Wu, J., Allen, G., Landavere, M., et al. (1996). Nitric oxide inhibits viral replication in murine myocarditis. The Journal of Clinical Investigation, 97(8), 1837–1843. doi:10.​1172/​JCI118613.PubMedCentralPubMed
130.
MacMicking, J. D., Nathan, C., Hom, G., Chartrain, N., Fletcher, D. S., Trumbauer, M., et al. (1995). Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell, 81(4), 641–650.PubMed
131.
Nishio, R., Matsumori, A., Shioi, T., Ishida, H., & Sasayama, S. (1999). Treatment of experimental viral myocarditis with interleukin-10. Circulation, 100(10), 1102–1108.PubMed
132.
Zaragoza, C., Ocampo, C. J., Saura, M., McMillan, A., & Lowenstein, C. J. (1997). Nitric oxide inhibition of coxsackievirus replication in vitro. The Journal of Clinical Investigation, 100(7), 1760–1767. doi:10.​1172/​JCI119702.PubMedCentralPubMed
133.
Zaragoza, C., Ocampo, C., Saura, M., Leppo, M., Wei, X. Q., Quick, R., et al. (1998). The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis. Proceedings of the National Academy of Sciences of the United States of America, 95(5), 2469–2474.PubMedCentralPubMed
134.
Jagtap, P., & Szabo, C. (2005). Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nature Reviews Drug Discovery, 4(5), 421–440. doi:10.​1038/​nrd1718.PubMed
135.
Levrand, S., Vannay-Bouchiche, C., Pesse, B., Pacher, P., Feihl, F., Waeber, B., et al. (2006). Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radical Biology & Medicine, 41(6), 886–895. doi:10.​1016/​j.​freeradbiomed.​2006.​04.​034.
136.
Liaudet, L., Szabo, E., Timashpolsky, L., Virag, L., Cziraki, A., & Szabo, C. (2001). Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences. British Journal of Pharmacology, 133(8), 1424–1430. doi:10.​1038/​sj.​bjp.​0704185.PubMed
137.
Mikami, S., Kawashima, S., Kanazawa, K., Hirata, K., Katayama, Y., Hotta, H., et al. (1996). Expression of nitric oxide synthase in a murine model of viral myocarditis induced by coxsackievirus B3. Biochemical and Biophysical Research Communications, 220(3), 983–989.PubMed
138.
Romorini, L., Scassa, M. E., Richardson, G. V., Bluguermann, C., de Giusti, C. J., Questa, M., et al. (2012). Activation of apoptotic signalling events in human embryonic stem cells upon Coxsackievirus B3 infection. Apoptosis : an International Journal on Programmed Cell Death, 17(2), 132–142. doi:10.​1007/​s10495-011-0668-z.
139.
Shimojo, T., Hiroe, M., Ishiyama, S., Ito, H., Nishikawa, T., & Marumo, F. (1999). Nitric oxide induces apoptotic death of cardiomyocytes via a cyclic-GMP-dependent pathway. Experimental Cell Research, 247(1), 38–47. doi:10.​1006/​excr.​1998.​4310.PubMed
140.
Eguchi, Y., Shimizu, S., & Tsujimoto, Y. (1997). Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Research, 57(10), 1835–1840.PubMed
141.
Sarszegi, Z., Bognar, E., Gaszner, B., Konyi, A., Gallyas, F., Jr., Sumegi, B., et al. (2012). BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Molecular and Cellular Biochemistry, 365(1–2), 129–137. doi:10.​1007/​s11010-012-1252-8.PubMed
142.
Song, Z. F., Chen, D. Y., Du, B., & Ji, X. P. (2013). Poly (ADP-ribose) polymerase inhibitor reduces heart ischaemia/reperfusion injury via inflammation and Akt signalling in rats. Chinese Medical Journal, 126(10), 1913–1917.PubMed
143.
Tao, R., Kim, S. H., Honbo, N., Karliner, J. S., & Alano, C. C. (2010). Minocycline protects cardiac myocytes against simulated ischemia-reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. Journal of Cardiovascular Pharmacology, 56(6), 659–668. doi:10.​1097/​FJC.​0b013e3181faeaf0​.PubMedCentralPubMed
144.
Serhan, C. N., & Savill, J. (2005). Resolution of inflammation: the beginning programs the end. Nature Immunology, 6(12), 1191–1197. doi:10.​1038/​ni1276.PubMed
Metadata
Title
Targeting Matrix Metalloproteinase Activity and Expression for the Treatment of Viral Myocarditis
Authors
Reid G. Hendry
Leanne M. Bilawchuk
David J. Marchant
Publication date
01-03-2014
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 2/2014
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-013-9528-2

Other articles of this Issue 2/2014

Journal of Cardiovascular Translational Research 2/2014 Go to the issue

OriginalPaper

Double-Blind Parallel Placebo-Controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients with Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention: the MEDCOR Trial

OriginalPaper

Should There Be Sex-Specific Criteria for the Diagnosis and Treatment of Heart Failure?

OriginalPaper

Relevance of Molecular Mimicry in the Mediation of Infectious Myocarditis

OriginalPaper

Blood Outgrowth Endothelial Cells Alter Remodeling of Completely Biological Engineered Grafts Implanted into the Sheep Femoral Artery

OriginalPaper

Sex Differences in Translocator Protein 18 kDa (TSPO) in the Heart: Implications for Imaging Myocardial Inflammation

OriginalPaper

The Role of Sex Differences in Autophagy in the Heart During Coxsackievirus B3-Induced Myocarditis